Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?

European Heart Journal

Volumn 31, Issue 14, 2010, Pages 1771-1779

  Lekawanvijit, Suree ^a   Adrahtas, Anastasia ^a   Kelly, Darren J ^b   Kompa, Andrew R ^a,b   Wang, Bing H ^a   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cell signalling; Cytokines; Fibrosis; Hypertrophy; Uraemic toxins

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDICAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUCINE; LEUCINE H 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROLINE DERIVATIVE; PROLINE H 3; TRITIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREMIC TOXIN;

ANIMAL CELL; ARTICLE; BIOASSAY; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG INHIBITION; FIBROBLAST; GENE EXPRESSION; HEART; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TH1 CELL; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, HYPERTROPHIC; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; INDICAN; KIDNEY FAILURE, CHRONIC; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TOXINS, BIOLOGICAL;

EID: 77954786480     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp574     Document Type: Article

References (41)

1. United States Renal Data Systems. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
2. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006;1:8-18.
3. Dhondt A, Vanholder R, Van Biesen W, Lameire N. The removal of uremic toxins. Kidney Int Suppl 2000;76:S47-S59.
4. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63: 1934-1943.
5. Stanfel LA, Gulyassy PF, Jarrard EA. Determination of indoxyl sulfate in plasma of patients with renal failure by use of ion-pairing liquid chromatography. Clin Chem 1986;32:938-942.
6. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994;124:96-104.
7. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R. Inconsistency of reported uremic toxin concentrations. Artif Organs 2007;31:600-611.
8. Swan JS, Kragten EY, Veening H. Liquid-chromatographic study of fluorescent materials in uremic fluids. Clin Chem 1983;29:1082-1084.
9. Niwa T, Takeda N, Tatematsu A, Maeda K. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem 1988;34:2264-2267.
10. Miyazaki T, Ise M, Seo H, Niwa T. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl 1997;62:S15-S22.
11. Lim CF, Bernard BF, de Jong M, Docter R, Krenning EP, Hennemann G. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993;76:318-324.
12. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004;65:442-451.
13. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007;5:1302-1308.
14. Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69:1780-1785.
15. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007;27:30-35.
16. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279-292.
17. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.
18. Tyralla K, Amann K. Cardiovascular changes in renal failure. Blood Purif 2002;20: 462-465. (Pubitemid 35007562)
19. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009;81:474-481.
20. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58: 88-111.
21. Stenvinkel P. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. Nephrol Ther 2006;2:111-119.
22. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004;15:2186-2194.
23. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, Haegeman G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactiva-tion mediated by tumor necrosis factor. J Biol Chem 1998;273:3285-3290.
24. Wang Y. Signal transduction in cardiac hypertrophy\dissecting compensatory versus pathological pathways utilizing a transgenic approach. Curr Opin Pharmacol 2001;1:134-140.
25. Cook SA, Sugden PH, Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischae-mic heart disease. J Mol Cell Cardiol 1999;31:1429-1434.
26. Ravingerova T, Barancik M, Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 2003;247:127-138.
27. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1-and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res 1985;56:884-894.
28. Woodcock EA, Wang BH, Arthur JF, Lennard A, Matkovich SJ, Du XJ, Brown JH, Hannan RD. Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. J Biol Chem 2002;277:22734-22742.
29. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 2004;44:1679-1689.
30. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 2002;90:135-142.
31. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 2008;294:H1804-H1814.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
33. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997;62:S23-S28.
34. Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med (Berlin, Germany) 1998;76:725-746.
35. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diab Res Clin Pract 2009;83:220-226.
36. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169. (Pubitemid 37337595)
37. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9:1018-1022.
38. Amann K, Neususs R, Ritz E, Irzyniec T, Wiest G, Mall G. Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hyper-tens 1995;8:409-417.
39. Iida S, Kohno K, Yoshimura J, Ueda S, Usui M, Miyazaki H, Nishida H, Tamaki K, Okuda S. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Clin Exp Nephrol 2006;10:262-267.
40. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 2000;15:1773-1781.
41. Nakagawa N, Hasebe N, Sumitomo K, Fujino T, Fukuzawa J, Hirayama T, Kikuchi K. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol 2006;26:455-461.